Inmune Bio (INMB) Other Accumulated Expenses (2020 - 2025)
Inmune Bio (INMB) posted Other Accumulated Expenses of $511000.0 for Q2 2025, up 6.46% sequentially from $480000.0 in Q1 2025, and down 1.92% YoY from $521000.0 in Q2 2024.
Inmune Bio (INMB) Other Accumulated Expenses (2020 - 2025) Analysis & Trends
Inmune Bio has reported Other Accumulated Expenses for 6 years, with the latest figure at $511000.0 in Q2 2025.
- Quarterly Other Accumulated Expenses fell 1.92% year-over-year to $511000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $511000.0 (down 1.92% YoY) and the FY2024 annual result came in at $517000.0, up 5.73% from the prior year.
- Other Accumulated Expenses climbed to $511000.0 in Q2 2025 per INMB's latest filing, from $480000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $778000.0 in Q3 2022 and troughed at $474000.0 in Q4 2021.
- A 5-year average of $548722.2 and a median of $531000.0 in 2021 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2023: Other Accumulated Expenses jumped 149.47% in 2021, then sank 36.25% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $474000.0 in 2021, then increased by 29.96% to $616000.0 in 2022, then decreased by 20.62% to $489000.0 in 2023, then advanced by 5.73% to $517000.0 in 2024, then decreased by 1.16% to $511000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $511000.0, $480000.0, and $517000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 511,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Dec 31, 2024 | 517,000.00 |
| Sep 30, 2024 | 549,000.00 |
| Jun 30, 2024 | 521,000.00 |
| Mar 31, 2024 | 520,000.00 |
| Dec 31, 2023 | 489,000.00 |
| Sep 30, 2023 | 496,000.00 |
| Jun 30, 2023 | 560,000.00 |
| Mar 31, 2023 | 591,000.00 |
| Dec 31, 2022 | 616,000.00 |
| Sep 30, 2022 | 778,000.00 |
| Jun 30, 2022 | 476,000.00 |
| Mar 31, 2022 | 584,000.00 |
| Dec 31, 2021 | 474,000.00 |
| Sep 30, 2021 | 541,000.00 |
| Jun 30, 2021 | 583,000.00 |
| Mar 31, 2021 | 591,000.00 |
| Dec 31, 2020 | 190,000.00 |
| Sep 30, 2020 | 253,709.00 |